Zocto News
News

Medtronic Raises Fiscal 2027 Forecasts Amid Strong Heart Device Demand

September 9, 2026
Medtronic Raises Fiscal 2027 Forecasts Amid Strong Heart Device Demand
3 views
AI Summary

Medtronic ups fiscal 2027 projections, citing robust demand for heart devices and strategic investments.

Medtronic has revised its fiscal 2027 projections upwards, driven by increasing demand for its heart devices used in complex cardiovascular procedures. The company now anticipates annual organic revenue growth between 7.25% and 7.75%, an increase from the previously projected 6.75% to 7.25% range. Additionally, Medtronic raised the lower end of its adjusted per-share profit forecast for fiscal 2027 to $5.94, maintaining the upper boundary at $6.

Strategic Investments and Market Expansion

As part of its growth strategy, Medtronic announced a substantial $80 million investment in Pi-Cardia, a maker of heart-valve repair devices, with an option to acquire the company for $210 million. Furthermore, Medtronic invested $700 million in Cornerstone Robotics, securing distribution rights for a robotic surgical device in select markets outside the United States. CEO Geoff Martha emphasized that these investments align with the company's focus on high-growth medtech segments and substantial patient pools.

During a recent earnings call, Martha highlighted the broad performance across Medtronic's business units and the significant contributions from new growth platforms. He noted the under-penetration of soft tissue robotic surgery in emerging markets, which Cornerstone's Sentire device aims to address, complementing Medtronic's existing Hugo device.

Financial Performance Highlights

In its latest quarterly report, Medtronic revealed a 19.5% increase in sales within its cardiovascular segment, reaching $3.93 billion. This surge was largely driven by an 88% growth in its pulsed field ablation portfolio, a treatment for irregular heart rhythms. The company reported an adjusted quarterly per-share profit of $1.45 on revenues of $9.76 billion, surpassing estimates of $1.39 per share on $9.55 billion in sales, according to data compiled by LSEG.

Medtronic's Chief Financial Officer Thierry Pieton mentioned that the company received tariff refunds nearly covering duties paid during the quarter. However, future refunds have not been factored into the company's outlook.

3 views